A vaccine for a coronavirus is a challenge and has never been very successful in the past. It’s difficult to do said a leading vaccine expert. 

An Australian expert in the development of vaccines tells the public not to have big expectations that a vaccine for the CCP Virus (coronavirus) will be available anytime soon, as that is unlikely.

Professor Ian Frazer from the University of Queensland was involved in successfully producing a vaccine for the human papillomavirus, which causes cervical cancer and took years of research.

Viruses that target the upper respiratory tract are hard to target with a vaccine, “It’s a separate immune system, if you like, which isn’t easily accessible by vaccine technology,” professor Frazer told the Health Report.

The cells of the upper respiratory tract work at preventing a virus from entering deep into the body and a strong immune response is thus not produced by the body, which makes it difficult to produce a vaccine for the virus.

“It’s a bit like trying to get a vaccine to kill a virus on the surface of your skin,” he said, reported the ABC.

“One of the problems with corona vaccines in the past has been that when the immune response does cross over to where the virus-infected cells are it actually increases the pathology rather than reducing it,” Frazer said. “So that immunization with SARS corona vaccine caused, in animals, inflammation in the lungs which wouldn’t otherwise have been there if the vaccine hadn’t been given.”

Frazer predicts that the vaccine that will be found useful is one that uses a part of the virus attached to a chemical to induce an immune response, or “subunit” vaccine.

“That [vaccine type] has been successful in animal models for coronaviruses in the past and that is of course where the money is being put in large measure at the moment,” he said.

“Another sort of vaccine would be just antibody transferred from somebody who had been infected already and had got rid of the infection.

“Which would be an immunological means of preventing infection, and could probably be more quickly developed than an actual vaccine,” he added

This illustration, reveals ultrastructural morphology exhibited by coronaviruses. (CDC)

Frazer said the production of a successful vaccine for the CCP Virus may be down the track, and plenty of research and money is going into finding one as soon as possible. “I think it would be fair to say even if we get something, which looked quite encouraging in animals, the safety trials in humans will have to be fairly extensive before we would think about vaccinating a group of people who have not yet been exposed to the virus.

“They might hope to get protection but certainly wouldn’t be keen to accept a possibility of really serious side effects if they actually caught the virus,” he said.

Meanwhile, all efforts are being made to accelerate the approval and production of CCP Virus vaccines, the National Institutes of Health has announced a public-private partnership with more than a dozen biopharmaceutical companies.

The U.S. Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), and the European Medicines Agency have signed on with world-class pharma companies to get a vaccine out amid the global CCP Virus pandemic.

President Trump said there are 35 different therapies and treatments being trialed on infected patients.

“HHS, FDA, CDC and the European Medicines Agency, they are all working together,” President Donald Trump told reporters at the White House Coronavirus Task Force daily briefing on Friday. “We are working together with a lot of other countries. The partnership will marshal and coordinate the vast resources, knowledge, assets, and authorities of more than a dozen organizations and agencies to accelerate development of the most promising therapies and vaccines.”